ZA200205161B - Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone. - Google Patents
Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone. Download PDFInfo
- Publication number
- ZA200205161B ZA200205161B ZA200205161A ZA200205161A ZA200205161B ZA 200205161 B ZA200205161 B ZA 200205161B ZA 200205161 A ZA200205161 A ZA 200205161A ZA 200205161 A ZA200205161 A ZA 200205161A ZA 200205161 B ZA200205161 B ZA 200205161B
- Authority
- ZA
- South Africa
- Prior art keywords
- mirtazapine
- gepirone
- combination
- treatment
- composition
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims description 74
- 229960001785 mirtazapine Drugs 0.000 title claims description 73
- 229960000647 gepirone Drugs 0.000 title claims description 68
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 title claims description 68
- 238000011282 treatment Methods 0.000 title claims description 44
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 22
- 208000020401 Depressive disease Diseases 0.000 title claims description 14
- 239000000890 drug combination Substances 0.000 title description 3
- 239000003814 drug Substances 0.000 claims description 46
- 239000000203 mixture Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000000506 psychotropic effect Effects 0.000 claims description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- 230000001976 improved effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 38
- 230000000694 effects Effects 0.000 description 35
- 239000000935 antidepressant agent Substances 0.000 description 17
- 230000001430 anti-depressive effect Effects 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 230000000949 anxiolytic effect Effects 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 239000002249 anxiolytic agent Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 229940005513 antidepressants Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000007958 sleep Effects 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 239000004579 marble Substances 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000002618 waking effect Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000001773 anti-convulsant effect Effects 0.000 description 4
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940001470 psychoactive drug Drugs 0.000 description 3
- 239000004089 psychotropic agent Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XUHLIQGRKRUKPH-ITZCMCNPSA-N 3-(Allylsulphinyl)-L-alanine Chemical compound OC(=O)[C@@H](N)CS(=O)CC=C XUHLIQGRKRUKPH-ITZCMCNPSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001229135 Nassa Species 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008503 anti depressant like effect Effects 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002898 effect on depression Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000576 supplementary effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200189 | 2000-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205161B true ZA200205161B (en) | 2003-09-29 |
Family
ID=8170928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205161A ZA200205161B (en) | 2000-01-19 | 2002-06-27 | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6835728B2 (ko) |
| EP (1) | EP1251854A2 (ko) |
| JP (1) | JP2003520237A (ko) |
| KR (1) | KR20020068404A (ko) |
| CN (1) | CN1223349C (ko) |
| AR (1) | AR027240A1 (ko) |
| AU (1) | AU780817B2 (ko) |
| BR (1) | BR0107721A (ko) |
| CA (1) | CA2396066A1 (ko) |
| CO (1) | CO5261583A1 (ko) |
| HK (1) | HK1047548A1 (ko) |
| HU (1) | HUP0204050A3 (ko) |
| IL (1) | IL150289A0 (ko) |
| MX (1) | MXPA02007095A (ko) |
| NO (1) | NO20023448L (ko) |
| PE (1) | PE20011049A1 (ko) |
| PL (1) | PL356605A1 (ko) |
| RU (1) | RU2268725C2 (ko) |
| SK (1) | SK10552002A3 (ko) |
| WO (1) | WO2001052855A2 (ko) |
| ZA (1) | ZA200205161B (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
| US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
| PE20070523A1 (es) | 2005-09-12 | 2007-06-28 | Wyeth Corp | Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona |
| GT200600414A (es) | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| GT200600416A (es) | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| EP1792618A1 (en) * | 2005-11-30 | 2007-06-06 | Rainer Freynhagen | R-mirtazapine for the treatment of pain |
| JP2009538334A (ja) * | 2006-05-22 | 2009-11-05 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 抑うつ障害のための治療 |
| TW200808804A (en) * | 2006-05-22 | 2008-02-16 | Organon Nv | Mirtazapine for the treatment of neuropathic pain |
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| CA2704117C (en) * | 2007-11-02 | 2015-11-17 | Acrux Dds Pty Ltd | Transdermal delivery system |
| EP2576520A1 (en) | 2010-05-28 | 2013-04-10 | GE Healthcare UK Limited | Radiolabeled compounds and methods thereof |
| GB201112987D0 (en) | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
| CN108743593B (zh) * | 2018-08-31 | 2019-03-26 | 程世宏 | 一种抗抑郁药物及其口服颗粒剂和制药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| US4423049A (en) * | 1981-12-28 | 1983-12-27 | Mead Johnson & Company | 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines |
| US4771053A (en) * | 1987-03-02 | 1988-09-13 | Bristol-Myers Company | Method for alleviation of primary depressive disorders |
| US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5011841B1 (en) * | 1989-11-14 | 1994-09-06 | Pfizer | Treatment of depression |
| GB9303968D0 (en) | 1993-02-26 | 1993-04-14 | Wyeth John & Brother Ltd | 5-ht1a ligands |
| GB9603136D0 (en) * | 1996-02-15 | 1996-04-17 | Merck Sharp & Dohme | Therapeutic agents |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
| ZA982368B (en) * | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
-
2001
- 2001-01-15 IL IL15028901A patent/IL150289A0/xx unknown
- 2001-01-15 WO PCT/EP2001/000407 patent/WO2001052855A2/en not_active Application Discontinuation
- 2001-01-15 RU RU2002122084/15A patent/RU2268725C2/ru not_active IP Right Cessation
- 2001-01-15 JP JP2001552902A patent/JP2003520237A/ja not_active Withdrawn
- 2001-01-15 HU HU0204050A patent/HUP0204050A3/hu unknown
- 2001-01-15 SK SK1055-2002A patent/SK10552002A3/sk not_active Application Discontinuation
- 2001-01-15 CN CNB018038654A patent/CN1223349C/zh not_active Expired - Fee Related
- 2001-01-15 MX MXPA02007095A patent/MXPA02007095A/es not_active Application Discontinuation
- 2001-01-15 AU AU25162/01A patent/AU780817B2/en not_active Ceased
- 2001-01-15 PL PL01356605A patent/PL356605A1/xx not_active Application Discontinuation
- 2001-01-15 US US10/181,843 patent/US6835728B2/en not_active Expired - Fee Related
- 2001-01-15 EP EP01900449A patent/EP1251854A2/en not_active Withdrawn
- 2001-01-15 KR KR1020027009276A patent/KR20020068404A/ko not_active Application Discontinuation
- 2001-01-15 CA CA002396066A patent/CA2396066A1/en not_active Abandoned
- 2001-01-15 BR BR0107721-0A patent/BR0107721A/pt not_active IP Right Cessation
- 2001-01-18 AR ARP010100214A patent/AR027240A1/es not_active Application Discontinuation
- 2001-01-18 PE PE2001000055A patent/PE20011049A1/es not_active Application Discontinuation
- 2001-01-18 CO CO01003479A patent/CO5261583A1/es not_active Application Discontinuation
-
2002
- 2002-06-27 ZA ZA200205161A patent/ZA200205161B/en unknown
- 2002-07-18 NO NO20023448A patent/NO20023448L/no not_active Application Discontinuation
- 2002-12-18 HK HK02109168.5A patent/HK1047548A1/zh unknown
-
2004
- 2004-11-22 US US10/996,213 patent/US20050090488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003520237A (ja) | 2003-07-02 |
| RU2002122084A (ru) | 2004-03-10 |
| HUP0204050A2 (hu) | 2003-03-28 |
| AU780817B2 (en) | 2005-04-21 |
| US20050090488A1 (en) | 2005-04-28 |
| CO5261583A1 (es) | 2003-03-31 |
| AR027240A1 (es) | 2003-03-19 |
| PE20011049A1 (es) | 2001-10-18 |
| PL356605A1 (en) | 2004-06-28 |
| EP1251854A2 (en) | 2002-10-30 |
| AU2516201A (en) | 2001-07-31 |
| NO20023448D0 (no) | 2002-07-18 |
| CN1223349C (zh) | 2005-10-19 |
| RU2268725C2 (ru) | 2006-01-27 |
| KR20020068404A (ko) | 2002-08-27 |
| NO20023448L (no) | 2002-09-17 |
| CN1395486A (zh) | 2003-02-05 |
| CA2396066A1 (en) | 2001-07-26 |
| SK10552002A3 (sk) | 2002-12-03 |
| MXPA02007095A (es) | 2003-04-14 |
| HUP0204050A3 (en) | 2004-09-28 |
| WO2001052855A8 (en) | 2002-12-27 |
| WO2001052855A3 (en) | 2002-01-10 |
| WO2001052855A2 (en) | 2001-07-26 |
| BR0107721A (pt) | 2002-10-01 |
| IL150289A0 (en) | 2002-12-01 |
| US20030105083A1 (en) | 2003-06-05 |
| HK1047548A1 (zh) | 2003-02-28 |
| US6835728B2 (en) | 2004-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100481254B1 (ko) | 미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물 | |
| US6835728B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
| US20080214592A1 (en) | Methods of treating anxiety disorders | |
| MX2014010939A (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. | |
| US9463181B2 (en) | Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders | |
| US10143676B2 (en) | Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders | |
| DE60026146T2 (de) | Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion | |
| US20080194631A1 (en) | Medicament For the Treatment of Central Nervous System Disorders | |
| US20080004284A1 (en) | Method for treating fibromyalgia syndrome and related conditions | |
| US20110034565A1 (en) | Psycho-pharmaceuticals | |
| AU2016203771A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| ZA200509904B (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
| MXPA05009850A (es) | Metodo para tratar el deterioro cognitivo leve y para prevenir o atrasar la enfermedad de alzheimer. | |
| CZ20022330A3 (cs) | Farmaceutický prostředek | |
| ES2284830T3 (es) | Uso de quetiapina para el tratamiento de la cocaina. | |
| IE930485A1 (en) | Antidepressant agents with a rapid onset of action | |
| WO2002016347A1 (en) | Active metabolite of gepirone | |
| WO2005097138A2 (en) | Combinations comprising oxcarbazepine to treat affective disorders | |
| AU2013203567A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| AU2013201492A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| EP1795199A2 (en) | Quetiapine for the treatment of substance dependence or substance abuse |